BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 20534551)

  • 21. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
    Ely S; Di Liberto M; Niesvizky R; Baughn LB; Cho HJ; Hatada EN; Knowles DM; Lane J; Chen-Kiang S
    Cancer Res; 2005 Dec; 65(24):11345-53. PubMed ID: 16357141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in
    Shi R; Li M; Raghavan V; Tam S; Cabanero M; Pham NA; Shepherd FA; Moghal N; Tsao MS
    Clin Cancer Res; 2018 Dec; 24(23):5990-6000. PubMed ID: 30093452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
    Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
    J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
    Wang L; Wang J; Blaser BW; Duchemin AM; Kusewitt DF; Liu T; Caligiuri MA; Briesewitz R
    Blood; 2007 Sep; 110(6):2075-83. PubMed ID: 17537993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
    Ramsey MR; Krishnamurthy J; Pei XH; Torrice C; Lin W; Carrasco DR; Ligon KL; Xiong Y; Sharpless NE
    Cancer Res; 2007 May; 67(10):4732-41. PubMed ID: 17510401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic mechanisms in glioblastoma multiforme.
    Nagarajan RP; Costello JF
    Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclin-dependent kinase 4/6 activity is a critical determinant of pre-replication complex assembly.
    Braden WA; McClendon AK; Knudsen ES
    Oncogene; 2008 Nov; 27(56):7083-93. PubMed ID: 18776921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct inhibition of retinoblastoma phosphorylation by nimbolide causes cell-cycle arrest and suppresses glioblastoma growth.
    Karkare S; Chhipa RR; Anderson J; Liu X; Henry H; Gasilina A; Nassar N; Ghosh J; Clark JP; Kumar A; Pauletti GM; Ghosh PK; Dasgupta B
    Clin Cancer Res; 2014 Jan; 20(1):199-212. PubMed ID: 24170547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.
    Miller TW; Traphagen NA; Li J; Lewis LD; Lopes B; Asthagiri A; Loomba J; De Jong J; Schiff D; Patel SH; Purow BW; Fadul CE
    J Neurooncol; 2019 Sep; 144(3):563-572. PubMed ID: 31399936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer.
    Zhao B; Burgess K
    Chem Commun (Camb); 2019 Feb; 55(18):2704-2707. PubMed ID: 30758029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.
    Guan KL; Jenkins CW; Li Y; Nichols MA; Wu X; O'Keefe CL; Matera AG; Xiong Y
    Genes Dev; 1994 Dec; 8(24):2939-52. PubMed ID: 8001816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme.
    Lam PY; Di Tomaso E; Ng HK; Pang JC; Roussel MF; Hjelm NM
    Br J Neurosurg; 2000 Feb; 14(1):28-32. PubMed ID: 10884881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers.
    Maust JD; Frankowski-McGregor CL; Bankhead A; Simeone DM; Sebolt-Leopold JS
    Mol Cancer Ther; 2018 Dec; 17(12):2495-2506. PubMed ID: 30254182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
    Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
    Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
    Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
    Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms.
    Skowron MA; Vermeulen M; Winkelhausen A; Becker TK; Bremmer F; Petzsch P; Schönberger S; Calaminus G; Köhrer K; Albers P; Nettersheim D
    Br J Cancer; 2020 Aug; 123(3):378-391. PubMed ID: 32418994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cooperative p16 and p21 action protects female astrocytes from transformation.
    Kfoury N; Sun T; Yu K; Rockwell N; Tinkum KL; Qi Z; Warrington NM; McDonald P; Roy A; Weir SJ; Mohila CA; Deneen B; Rubin JB
    Acta Neuropathol Commun; 2018 Feb; 6(1):12. PubMed ID: 29458417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
    Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T
    Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
    Kirsch M; Mörz M; Pinzer T; Schackert HK; Schackert G
    Genes Chromosomes Cancer; 2009 Feb; 48(2):143-54. PubMed ID: 18973139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.